Hearscape

Evidence Library

This is the source layer behind the map. Use it to check where a claim came from and exactly what that source supports.

Source Links
935
public sources attached to records
Unique Websites
899
duplicate links counted once
Reviewed Records
481
2026-06-10 latest review
Data Checks
13/13
passing validation checks

Where Sources Come From

Sources are grouped by what they are, not by how favorable they sound.

Company Source
446
Clinical Trial Registry
298
Publication
92
Regulatory Source
38
Trial Registry Mirror
27
Public Database
11
Institution Source
11
Expert Review
4
Compound Database
2
Website Check
2
Manual Curation
2
Drug Label
1
Protein Database
1
Source

Where the information came from, such as a trial registry, publication, company page, or regulatory record.

Evidence Rating

A plain-language summary of the public evidence attached to the record.

What This Source Confirms

The specific parts of the record backed up by that source, such as company, stage, indication, or trial ID.

935 sources · 481 records · 935 with source linksShowing first 200; export includes all filtered rows.
Program and SourceEvidenceConfirmed DetailsReview
Otarmeni by Regeneron
Regeneron Pharmaceuticals
TherapeuticGene Therapy
Regulatory Sourcefda.gov
Regulatory Source
Priority: Top priority
Confidence: 99%
ApprovedApproved
Program NameAlternative NamesCompany or SponsorDevelopment StageCurrent Status+2
ID: Otarmeni, DB-OTO
2026-05-31
Open source
Otarmeni by Regeneron
Regeneron Pharmaceuticals
TherapeuticGene Therapy
Company Sourceinvestor.regeneron.com
Regulatory Source
Priority: Top priority
Confidence: 99%
ApprovedApproved
Company or SponsorRelated CompaniesMechanismRoute of AdministrationPatient Population+1
ID: DB-OTO, Otarmeni
2026-05-31
Open source
Otarmeni by Regeneron
Regeneron Pharmaceuticals
TherapeuticGene Therapy
Clinical Trial Registryclinicaltrials.gov
Regulatory Source
Priority: Top priority
Confidence: 99%
ApprovedApproved
Trial IDsRoute of AdministrationPatient PopulationGeography
ID: NCT05788536
2026-05-31
Open source
PEDMARK by Fennec Pharmaceuticals
Fennec Pharmaceuticals
TherapeuticSmall Molecule
Regulatory Sourcefda.gov
Regulatory Source
Priority: Top priority
Confidence: 98%
MarketedMarketed
Program NameCompany or SponsorDevelopment StageCurrent StatusIndications+1
ID: PEDMARK
2026-05-31
Open source
PEDMARK by Fennec Pharmaceuticals
Fennec Pharmaceuticals
TherapeuticSmall Molecule
Regulatory Sourceaccessdata.fda.gov
Regulatory Source
Priority: Top priority
Confidence: 98%
MarketedMarketed
Route of AdministrationPatient PopulationNotes
ID: 212937
2026-05-31
Open source
PEDMARK by Fennec Pharmaceuticals
Fennec Pharmaceuticals
TherapeuticSmall Molecule
Company Sourceinvestors.fennecpharma.com
Regulatory Source
Priority: Top priority
Confidence: 98%
MarketedMarketed
Alternative NamesGeographyRelated Companies
ID: PEDMARQSI
2026-05-31
Open source
Apple AirPods Pro Hearing Health Features
Apple
Software/NeurotechHearing Aid/Software
Regulatory Sourcefda.gov
Regulatory Source
Priority: Top priority
Confidence: 97%
MarketedMarketed
Program NameCompany or SponsorTreatment or Product TypeDevelopment StageCurrent Status+2
ID: DEN230081
2026-05-31
Open source
Apple AirPods Pro Hearing Health Features
Apple
Software/NeurotechHearing Aid/Software
Company Sourceapple.com
Regulatory Source
Priority: Top priority
Confidence: 97%
MarketedMarketed
MechanismIndicationsRoute of AdministrationNotes
No source ID listed
2026-05-31
Open source
Apple AirPods Pro Hearing Health Features
Apple
Software/NeurotechHearing Aid/Software
Company Sourcesupport.apple.com
Regulatory Source
Priority: Top priority
Confidence: 97%
MarketedMarketed
Alternative NamesCurrent StatusGeographyPatient Population
No source ID listed
2026-05-31
Open source
Envoy Medical Esteem Fully Implanted Hearing System
Envoy Medical
DeviceActive Middle Ear Implant
Company Sourceenvoymedical.com
Regulatory Source
Priority: Main database
Confidence: 97%
MarketedMarketed
Program NameAlternative NamesCompany or SponsorMechanismIndications+2
No source ID listed
2026-06-10
Open source
Envoy Medical Esteem Fully Implanted Hearing System
Envoy Medical
DeviceActive Middle Ear Implant
Regulatory Sourceaccessdata.fda.gov
Regulatory Source
Priority: Main database
Confidence: 97%
MarketedMarketed
Development StageCurrent StatusPatient PopulationNotesKey Events
ID: P090018
2026-06-10
Open source
Envoy Medical Esteem Fully Implanted Hearing System
Envoy Medical
DeviceActive Middle Ear Implant
Company Sourceenvoymedical.com
Regulatory Source
Priority: Main database
Confidence: 97%
MarketedMarketed
NotesCurrent Status
No source ID listed
2026-06-10
Open source
BHM contact mini Bone Conduction System
BHM-Tech
DeviceBone Conduction Hearing System
Company Sourcebhm-tech.at
Company Source
Priority: Priority 3
Confidence: 77%
MarketedMarketed
Program NameAlternative NamesCompany or SponsorMechanismCurrent Status+2
No source ID listed
2026-06-10
Open source
BHM contact mini Bone Conduction System
BHM-Tech
DeviceBone Conduction Hearing System
Company Sourcebhm-tech.at
Company Source
Priority: Priority 3
Confidence: 77%
MarketedMarketed
NotesRelated Companies
No source ID listed
2026-06-10
Open source
BHM contact forte Bone Conduction System
BHM-Tech
DeviceBone Conduction Hearing System
Company Sourcebhm-tech.at
Company Source
Priority: Priority 3
Confidence: 77%
MarketedMarketed
Program NameAlternative NamesCompany or SponsorMechanismCurrent Status+2
No source ID listed
2026-06-10
Open source
BHM contact forte Bone Conduction System
BHM-Tech
DeviceBone Conduction Hearing System
Company Sourcebhm-tech.at
Company Source
Priority: Priority 3
Confidence: 77%
MarketedMarketed
NotesRelated Companies
No source ID listed
2026-06-10
Open source
BHM contact star evo1 Bone Conduction Glasses
BHM-Tech
DeviceBone Conduction Hearing System
Company Sourcebhm-tech.at
Company Source
Priority: Priority 3
Confidence: 77%
MarketedMarketed
Program NameAlternative NamesCompany or SponsorMechanismCurrent Status+2
No source ID listed
2026-06-10
Open source
BHM contact star evo1 Bone Conduction Glasses
BHM-Tech
DeviceBone Conduction Hearing System
Company Sourcebhm-tech.at
Company Source
Priority: Priority 3
Confidence: 77%
MarketedMarketed
NotesRelated Companies
No source ID listed
2026-06-10
Open source
Lenire Tinnitus Treatment Device
Neuromod Devices
DeviceNeuromodulation
Regulatory Sourceaccessdata.fda.gov
Regulatory Source
Priority: Top priority
Confidence: 97%
MarketedMarketed
Program NameCompany or SponsorTreatment or Product TypeDevelopment StageCurrent Status+2
ID: DEN210033
2026-05-31
Open source
Lenire Tinnitus Treatment Device
Neuromod Devices
DeviceNeuromodulation
Company Sourcelenire.com
Regulatory Source
Priority: Top priority
Confidence: 97%
MarketedMarketed
Alternative NamesMechanismIndicationsRoute of AdministrationGeography
No source ID listed
2026-05-31
Open source
Bose SoundControl Hearing Aids
Bose
DeviceHearing Aid/Software
Regulatory Sourceaccessdata.fda.gov
Regulatory Source
Priority: Main database
Confidence: 96%
MarketedDiscontinued
Program NameCompany or SponsorNotesKey Events
ID: DEN180026
2026-05-31
Open source
Bose SoundControl Hearing Aids
Bose
DeviceHearing Aid/Software
Regulatory Sourceaccessdata.fda.gov
Regulatory Source
Priority: Main database
Confidence: 96%
MarketedDiscontinued
Alternative NamesMechanismIndicationsDevelopment StageRoute of Administration
ID: K211008
2026-05-31
Open source
Bose SoundControl Hearing Aids
Bose
DeviceHearing Aid/Software
Company Sourcelexiehearing.com
Regulatory Source
Priority: Main database
Confidence: 96%
MarketedDiscontinued
Current StatusRelated CompaniesNotesKey Events
No source ID listed
2026-05-31
Open source
Cochlear Osia System
Cochlear
DeviceCochlear/Auditory Implant
Company Sourcecochlear.com
Regulatory Source
Priority: Main database
Confidence: 96%
MarketedMarketed
Program NameAlternative NamesCompany or SponsorTreatment or Product TypeMechanism+3
No source ID listed
2026-05-31
Open source
Cochlear Osia System
Cochlear
DeviceCochlear/Auditory Implant
Regulatory Sourceaccessdata.fda.gov
Regulatory Source
Priority: Main database
Confidence: 96%
MarketedMarketed
Alternative NamesDevelopment StageCurrent StatusGeographyNotes
ID: K231204
2026-05-31
Open source
Cochlear Osia System
Cochlear
DeviceCochlear/Auditory Implant
Company Sourcecochlear.com
Regulatory Source
Priority: Main database
Confidence: 96%
MarketedMarketed
Key EventsNotesGeography
No source ID listed
2026-05-31
Open source
FX-322 by Frequency Therapeutics
Frequency Therapeutics
TherapeuticRegenerative Medicine
Company Sourcebusinesswire.com
Company Source
Priority: Top priority
Confidence: 96%
Phase 2Discontinued
Program NameAlternative NamesDevelopment StageCurrent StatusIndications+2
ID: FX-322, FX-322-208
2026-05-31
Open source
FX-322 by Frequency Therapeutics
Frequency Therapeutics
TherapeuticRegenerative Medicine
Company Sourcesec.gov
Company Source
Priority: Top priority
Confidence: 96%
Phase 2Discontinued
MechanismRoute of AdministrationNotes
ID: FX-322
2026-05-31
Open source
FX-322 by Frequency Therapeutics
Frequency Therapeutics
TherapeuticRegenerative Medicine
Clinical Trial Registryclinicaltrials.gov
Company Source
Priority: Top priority
Confidence: 96%
Phase 2Discontinued
Trial IDsDevelopment StageRoute of AdministrationIndications
ID: NCT04120116
2026-05-31
Open source
OTO-313 by Otonomy
Otonomy
TherapeuticSmall Molecule
Company Sourceglobenewswire.com
Company Source
Priority: Main database
Confidence: 96%
Phase 2Discontinued
Program NameAlternative NamesDevelopment StageCurrent StatusIndications+1
ID: OTO-313
2026-05-31
Open source
OTO-313 by Otonomy
Otonomy
TherapeuticSmall Molecule
Company Sourcesec.gov
Company Source
Priority: Main database
Confidence: 96%
Phase 2Discontinued
MechanismRoute of AdministrationPatient Population
ID: OTO-313
2026-05-31
Open source
OTO-313 by Otonomy
Otonomy
TherapeuticSmall Molecule
Company Sourcesec.gov
Company Source
Priority: Main database
Confidence: 96%
Phase 2Discontinued
Company or SponsorRelated Companies
ID: Otonomy
2026-05-31
Open source
AK-OTOF by Eli Lilly and Akouos
Eli Lilly and Company
TherapeuticGene Therapy
Clinical Trial Registryclinicaltrials.gov
Clinical Trial
Priority: Top priority
Confidence: 95%
Phase 2Active
Program NameAlternative NamesTrial IDsRoute of AdministrationPatient Population+1
ID: NCT05821959
2026-05-31
Open source
AK-OTOF by Eli Lilly and Akouos
Eli Lilly and Company
TherapeuticGene Therapy
Company Sourceinvestor.lilly.com
Clinical Trial
Priority: Top priority
Confidence: 95%
Phase 2Active
Company or SponsorRelated CompaniesDevelopment StageCurrent StatusIndications
ID: OTOF Gene Therapy
2026-05-31
Open source
AK-OTOF by Eli Lilly and Akouos
Eli Lilly and Company
TherapeuticGene Therapy
Company Sourceinvestor.lilly.com
Clinical Trial
Priority: Top priority
Confidence: 95%
Phase 2Active
Company or SponsorRelated CompaniesMechanismTarget Gene
ID: AK-OTOF
2026-05-31
Open source
AM-111 by Auris Medical and Altamira
Altamira Therapeutics
TherapeuticBiologic
Company Sourceglobenewswire.com
Company Source
Priority: Main database
Confidence: 95%
Phase 3Discontinued
Program NameAlternative NamesDevelopment StageCurrent StatusIndications+1
ID: AM-111, Sonsuvi
2026-05-31
Open source
AM-111 by Auris Medical and Altamira
Altamira Therapeutics
TherapeuticBiologic
Company Sourcesec.gov
Company Source
Priority: Main database
Confidence: 95%
Phase 3Discontinued
Company or SponsorRelated CompaniesRoute of AdministrationNotes
ID: AM-111, Sonsuvi
2026-05-31
Open source
AM-111 by Auris Medical and Altamira
Altamira Therapeutics
TherapeuticBiologic
Publicationml.globenewswire.com
Company Source
Priority: Main database
Confidence: 95%
Phase 3Discontinued
Notes
ID: HEALOS
2026-05-31
Open source
Cochlear Nucleus ABI541 Brainstem Implant
Cochlear
DeviceBCI/Neurotech
Regulatory Sourceaccessdata.fda.gov
Regulatory Source
Priority: Main database
Confidence: 95%
ApprovedApproved
Program NameCompany or SponsorTreatment or Product TypeMechanismIndications+3
ID: P000015S012
2026-05-31
Open source
Cochlear Nucleus ABI541 Brainstem Implant
Cochlear
DeviceBCI/Neurotech
Company Sourceassets.cochlear.com
Regulatory Source
Priority: Main database
Confidence: 95%
ApprovedApproved
Alternative NamesRoute of AdministrationNotesGeography
No source ID listed
2026-05-31
Open source
FX-345 by Frequency Therapeutics
Frequency Therapeutics
TherapeuticRegenerative Medicine
Company Sourcebusinesswire.com
Company Source
Priority: Main database
Confidence: 95%
Phase 1Discontinued
Program NameAlternative NamesDevelopment StageRoute of AdministrationCompany or Sponsor+1
ID: FX-345, FX-345-101
2026-05-31
Open source
FX-345 by Frequency Therapeutics
Frequency Therapeutics
TherapeuticRegenerative Medicine
Company Sourcebusinesswire.com
Company Source
Priority: Main database
Confidence: 95%
Phase 1Discontinued
Current StatusNotes
ID: FX-345
2026-05-31
Open source
MED-EL VIBRANT SOUNDBRIDGE
MED-EL
DeviceCochlear/Auditory Implant
Company Sourcemedel.com
Regulatory Source
Priority: Main database
Confidence: 95%
MarketedMarketed
Program NameMechanismIndicationsRoute of AdministrationCurrent Status
No source ID listed
2026-05-31
Open source
MED-EL VIBRANT SOUNDBRIDGE
MED-EL
DeviceCochlear/Auditory Implant
Regulatory Sourceaccessdata.fda.gov
Regulatory Source
Priority: Main database
Confidence: 95%
MarketedMarketed
Company or SponsorDevelopment StagePatient PopulationGeographyNotes
ID: P990052
2026-05-31
Open source
Nuance Audio Hearing Aid Software
EssilorLuxottica
Software/NeurotechHearing Aid/Software
Company Sourceessilorluxottica.com
Regulatory Source
Priority: Top priority
Confidence: 95%
MarketedMarketed
Program NameCompany or SponsorDevelopment StageCurrent StatusGeography+1
No source ID listed
2026-05-31
Open source
Nuance Audio Hearing Aid Software
EssilorLuxottica
Software/NeurotechHearing Aid/Software
Regulatory Sourceaccessdata.fda.gov
Regulatory Source
Priority: Top priority
Confidence: 95%
MarketedMarketed
Alternative NamesMechanismIndicationsPatient PopulationRoute of Administration
ID: K243150
2026-05-31
Open source
Nuance Audio Hearing Aid Software
EssilorLuxottica
Software/NeurotechHearing Aid/Software
Company Sourcenuanceaudio.com
Regulatory Source
Priority: Top priority
Confidence: 95%
MarketedMarketed
Current StatusNotesRoute of Administration
No source ID listed
2026-05-31
Open source
OTO-413 by Otonomy
Otonomy
TherapeuticBiologic
Company Sourceglobenewswire.com
Company Source
Priority: Main database
Confidence: 95%
Phase 2Discontinued
Program NameAlternative NamesDevelopment StageCurrent StatusNotes
ID: OTO-413
2026-05-31
Open source
OTO-413 by Otonomy
Otonomy
TherapeuticBiologic
Company Sourcesec.gov
Company Source
Priority: Main database
Confidence: 95%
Phase 2Discontinued
MechanismIndicationsRoute of AdministrationPatient Population
ID: OTO-413
2026-05-31
Open source
OTO-413 by Otonomy
Otonomy
TherapeuticBiologic
Company Sourcesec.gov
Company Source
Priority: Main database
Confidence: 95%
Phase 2Discontinued
Company or SponsorRelated CompaniesNotes
ID: Otonomy
2026-05-31
Open source
Cochlear Nucleus Nexa System
Cochlear
DeviceCochlear/Auditory Implant
Company Sourcecochlear.com
Company Source
Priority: Top priority
Confidence: 94%
MarketedMarketed
Program NameAlternative NamesCompany or SponsorProgram CategoryTreatment or Product Type+4
No source ID listed
2026-05-31
Open source
Cochlear Nucleus Nexa System
Cochlear
DeviceCochlear/Auditory Implant
Company Sourcecochlear.com
Company Source
Priority: Top priority
Confidence: 94%
MarketedMarketed
Development StageCurrent StatusNotesKey EventsGeography
No source ID listed
2026-05-31
Open source
Oticon Medical Neuro System
Oticon Medical / Demant
DeviceCochlear/Auditory Implant
Company Sourceoticonmedical.com
Regulatory Source
Priority: Main database
Confidence: 94%
MarketedDiscontinued
Program NameAlternative NamesCompany or SponsorCurrent StatusNotes+1
No source ID listed
2026-05-31
Open source
Oticon Medical Neuro System
Oticon Medical / Demant
DeviceCochlear/Auditory Implant
Regulatory Sourceaccessdata.fda.gov
Regulatory Source
Priority: Main database
Confidence: 94%
MarketedDiscontinued
MechanismIndicationsDevelopment StageGeography
ID: P200021
2026-05-31
Open source
Oticon Medical Neuro System
Oticon Medical / Demant
DeviceCochlear/Auditory Implant
Company Sourcedemant.com
Regulatory Source
Priority: Main database
Confidence: 94%
MarketedDiscontinued
Current StatusRelated CompaniesNotesKey Events
No source ID listed
2026-05-31
Open source
SENS-401 (Arazasetron) by Sensorion
Sensorion
TherapeuticSmall Molecule
Company Sourcesensorion.com
Company Source
Priority: Top priority
Confidence: 94%
Phase 2Active
Program NameAlternative NamesCompany or SponsorRelated CompaniesMechanism+3
ID: SENS-401, Arazasetron, R-azasetron besylate
2026-06-09
Open source
SENS-401 (Arazasetron) by Sensorion
Sensorion
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Company Source
Priority: Top priority
Confidence: 94%
Phase 2Active
Trial IDsDevelopment StagePatient PopulationGeography
ID: NCT03603314
2026-06-09
Open source
SENS-401 (Arazasetron) by Sensorion
Sensorion
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Company Source
Priority: Top priority
Confidence: 94%
Phase 2Active
Alternative NamesTrial IDsDevelopment StagePatient PopulationGeography+1
ID: NCT05258773, SENS-401 (R-Azasetron Besylate)
2026-06-09
Open source
SENS-401 (Arazasetron) by Sensorion
Sensorion
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Company Source
Priority: Top priority
Confidence: 94%
Phase 2Active
Alternative NamesTrial IDsDevelopment StageIndicationsPatient Population+2
ID: NCT05628233, SENS-401 (R-Azasetron Besylate), cisplatin-induced ototoxicity
2026-06-09
Open source
SENS-401 (Arazasetron) by Sensorion
Sensorion
TherapeuticSmall Molecule
Company Sourcebiospace.com
Company Source
Priority: Top priority
Confidence: 94%
Phase 2Active
Development StageCurrent StatusIndicationsRoute of AdministrationNotes+1
ID: NOTOXIS, SENS-401, NCT05628233
2026-06-09
Open source
SENS-401 (Arazasetron) by Sensorion
Sensorion
TherapeuticSmall Molecule
Publicationpubmed.ncbi.nlm.nih.gov
Company Source
Priority: Top priority
Confidence: 94%
Phase 2Active
MechanismNotes
ID: 39173396
2026-06-09
Open source
SENS-501 by Sensorion
Sensorion
TherapeuticGene Therapy
Clinical Trial Registryclinicaltrials.gov
Clinical Trial
Priority: Top priority
Confidence: 94%
Phase 1/2Active
Program NameAlternative NamesTrial IDsDevelopment StageRoute of Administration+2
ID: NCT06370351
2026-05-31
Open source
SENS-501 by Sensorion
Sensorion
TherapeuticGene Therapy
Company Sourcesensorion.com
Clinical Trial
Priority: Top priority
Confidence: 94%
Phase 1/2Active
Company or SponsorRelated CompaniesMechanismTarget GeneIndications
ID: SENS-501, OTOF-GT
2026-05-31
Open source
SENS-501 by Sensorion
Sensorion
TherapeuticGene Therapy
Company Sourcebiospace.com
Clinical Trial
Priority: Top priority
Confidence: 94%
Phase 1/2Active
Current StatusDevelopment StageNotes
ID: SENS-501
2026-05-31
Open source
ACOU085 by Acousia Therapeutics
Acousia Therapeutics GmbH
TherapeuticSmall Molecule
Company Sourceacousia.com
Company Source
Priority: Main database
Confidence: 93%
Phase 2Active
Program NameAlternative NamesCompany or SponsorTreatment or Product TypeMechanism+7
ID: ACOU085, Bimokalner, PROHEAR
2026-05-31
Open source
ACOU085 by Acousia Therapeutics
Acousia Therapeutics GmbH
TherapeuticSmall Molecule
Company Sourceacousia.com
Company Source
Priority: Main database
Confidence: 93%
Phase 2Active
IndicationsDevelopment StagePatient PopulationKey Events
ID: ACOU085
2026-05-31
Open source
ACOU085 by Acousia Therapeutics
Acousia Therapeutics GmbH
TherapeuticSmall Molecule
Company Sourceacousia.com
Company Source
Priority: Main database
Confidence: 93%
Phase 2Active
Development StageCurrent StatusPatient PopulationKey Events
ID: ACOU085
2026-05-31
Open source
ACOU085 by Acousia Therapeutics
Acousia Therapeutics GmbH
TherapeuticSmall Molecule
Company Sourceacousia.com
Company Source
Priority: Main database
Confidence: 93%
Phase 2Active
Company or SponsorRelated CompaniesIndicationsNotes
ID: ACOU085, ACOU082
2026-05-31
Open source
ACOU085 by Acousia Therapeutics
Acousia Therapeutics GmbH
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Company Source
Priority: Main database
Confidence: 93%
Phase 2Active
Trial IDsDevelopment StageCurrent StatusRoute of AdministrationPatient Population+1
ID: NCT06521190
2026-05-31
Open source
AM-101 by Auris Medical and Altamira
Altamira Therapeutics
TherapeuticSmall Molecule
Company Sourceglobenewswire.com
Clinical Trial
Priority: Main database
Confidence: 93%
Phase 3Discontinued
Program NameAlternative NamesIndicationsNotes
ID: AM-101, Keyzilen
2026-05-31
Open source
AM-101 by Auris Medical and Altamira
Altamira Therapeutics
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Clinical Trial
Priority: Main database
Confidence: 93%
Phase 3Discontinued
Trial IDsDevelopment StageRoute of Administration
ID: NCT02040194
2026-05-31
Open source
AM-101 by Auris Medical and Altamira
Altamira Therapeutics
TherapeuticSmall Molecule
Company Sourcesec.gov
Clinical Trial
Priority: Main database
Confidence: 93%
Phase 3Discontinued
Company or SponsorRelated CompaniesCurrent Status
ID: AM-101, Keyzilen
2026-05-31
Open source
Envoy Medical Acclaim Cochlear Implant
Envoy Medical
DeviceCochlear/Auditory Implant
Company Sourceenvoymedical.com
Clinical Trial
Priority: Top priority
Confidence: 93%
Phase 2/3Active
Program NameCompany or SponsorMechanismCurrent StatusRoute of Administration+1
No source ID listed
2026-05-31
Open source
Envoy Medical Acclaim Cochlear Implant
Envoy Medical
DeviceCochlear/Auditory Implant
Clinical Trial Registryclinicaltrials.gov
Clinical Trial
Priority: Top priority
Confidence: 93%
Phase 2/3Active
Development StageCurrent StatusTrial IDsGeography
ID: NCT06699797
2026-05-31
Open source
Envoy Medical Acclaim Cochlear Implant
Envoy Medical
DeviceCochlear/Auditory Implant
Company Sourceenvoymedical.com
Clinical Trial
Priority: Top priority
Confidence: 93%
Phase 2/3Active
Key EventsNotes
No source ID listed
2026-05-31
Open source
GSI Audera Pro
Grason-Stadler
DiagnosticDiagnostic
Company Sourcegrason-stadler.com
Regulatory Source
Priority: Priority 3
Confidence: 93%
MarketedMarketed
Program NameCompany or SponsorMechanismCurrent StatusRoute of Administration
No source ID listed
2026-05-31
Open source
GSI Audera Pro
Grason-Stadler
DiagnosticDiagnostic
Regulatory Sourceaccessdata.fda.gov
Regulatory Source
Priority: Priority 3
Confidence: 93%
MarketedMarketed
Alternative NamesIndicationsDevelopment StagePatient PopulationGeography
ID: K193033
2026-05-31
Open source
MED-EL SYNCHRONY Cochlear Implant System
MED-EL
DeviceCochlear/Auditory Implant
Company Sourcemedel.com
Regulatory Source
Priority: Top priority
Confidence: 93%
MarketedMarketed
Program NameCompany or SponsorProgram CategoryTreatment or Product TypeIndications+2
No source ID listed
2026-05-31
Open source
MED-EL SYNCHRONY Cochlear Implant System
MED-EL
DeviceCochlear/Auditory Implant
Regulatory Sourceaccessdata.fda.gov
Regulatory Source
Priority: Top priority
Confidence: 93%
MarketedMarketed
MechanismIndicationsDevelopment StagePatient PopulationNotes
ID: P000025, P000025S129
2026-05-31
Open source
CIL001 (Paliroden) by Cilcare
Cilcare SAS
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Clinical Trial
Priority: Main database
Confidence: 92%
Phase 1/2Active
Program NameAlternative NamesCompany or SponsorDevelopment StageCurrent Status+5
ID: NCT07472907, RESPLAND, CIL001, Paliroden
2026-06-08
Open source
CIL001 (Paliroden) by Cilcare
Cilcare SAS
TherapeuticSmall Molecule
Company Sourcecilcare.com
Clinical Trial
Priority: Main database
Confidence: 92%
Phase 1/2Active
Company or SponsorTreatment or Product TypeMechanismIndicationsNotes
ID: CIL001
2026-06-08
Open source
CIL001 (Paliroden) by Cilcare
Cilcare SAS
TherapeuticSmall Molecule
Company Sourcecilcare.com
Clinical Trial
Priority: Main database
Confidence: 92%
Phase 1/2Active
Development StageCurrent StatusIndicationsNotes
ID: CIL001
2026-06-08
Open source
Cochlear Baha System
Cochlear
DeviceCochlear/Auditory Implant
Company Sourcecochlear.com
Company Source
Priority: Main database
Confidence: 92%
MarketedMarketed
Program NameAlternative NamesCompany or SponsorMechanismIndications+2
No source ID listed
2026-06-10
Open source
Cochlear Baha System
Cochlear
DeviceCochlear/Auditory Implant
Company Sourcecochlear.com
Company Source
Priority: Main database
Confidence: 92%
MarketedMarketed
Development StageCurrent StatusGeographyNotes
No source ID listed
2026-06-10
Open source
Cochlear Baha System
Cochlear
DeviceCochlear/Auditory Implant
Regulatory Sourceaccessdata.fda.gov
Company Source
Priority: Main database
Confidence: 92%
MarketedMarketed
Development StageRoute of Administration
ID: K121317
2026-06-10
Open source
NS101 by Neuracle Science
Neuracle Science Co., Ltd.
TherapeuticBiologic
Clinical Trial Registryclinicaltrials.gov
Clinical Trial
Priority: Main database
Confidence: 92%
Phase 1/2Active
Program NameCompany or SponsorDevelopment StageCurrent StatusRoute of Administration+5
ID: NCT06249919, NS101, FAM19A5
2026-06-08
Open source
NS101 by Neuracle Science
Neuracle Science Co., Ltd.
TherapeuticBiologic
Company Sourceneuracles.com
Clinical Trial
Priority: Main database
Confidence: 92%
Phase 1/2Active
Company or SponsorTreatment or Product TypeMechanismIndicationsNotes
ID: NS101, FAM19A5
2026-06-08
Open source
NS101 by Neuracle Science
Neuracle Science Co., Ltd.
TherapeuticBiologic
Company Sourceneuracles.com
Clinical Trial
Priority: Main database
Confidence: 92%
Phase 1/2Active
Current StatusIndicationsNotes
ID: NS101
2026-06-08
Open source
Phonak Audéo Sphere Infinio
Phonak
DeviceHearing Aid/Software
Company Sourcephonak.com
Company Source
Priority: Top priority
Confidence: 92%
MarketedMarketed
Program NameAlternative NamesCompany or SponsorMechanismIndications+2
No source ID listed
2026-05-31
Open source
Phonak Audéo Sphere Infinio
Phonak
DeviceHearing Aid/Software
Company Sourcephonak.com
Company Source
Priority: Top priority
Confidence: 92%
MarketedMarketed
NotesDevelopment StageGeography
No source ID listed
2026-05-31
Open source
DB-020 by Regeneron and Decibel
Regeneron Pharmaceuticals
TherapeuticDrug Delivery
Clinical Trial Registryclinicaltrials.gov
Publication
Priority: Main database
Confidence: 92%
Phase 1Completed
Program NameAlternative NamesTrial IDsRoute of AdministrationPatient Population+1
ID: NCT04262336
2026-05-31
Open source
DB-020 by Regeneron and Decibel
Regeneron Pharmaceuticals
TherapeuticDrug Delivery
Publicationpubmed.ncbi.nlm.nih.gov
Publication
Priority: Main database
Confidence: 92%
Phase 1Completed
MechanismIndicationsDevelopment StageCurrent StatusNotes
ID: 40403227
2026-05-31
Open source
DB-020 by Regeneron and Decibel
Regeneron Pharmaceuticals
TherapeuticDrug Delivery
Regulatory Sourcecancer.gov
Publication
Priority: Main database
Confidence: 92%
Phase 1Completed
MechanismNotes
ID: DB-020
2026-05-31
Open source
Rincell-1 by Rinri Therapeutics
Rinri Therapeutics
TherapeuticCell Therapy
Company Sourcerinri-therapeutics.com
Clinical Trial
Priority: Top priority
Confidence: 92%
Phase 1/2Active
Program NameAlternative NamesCompany or SponsorMechanismIndications+2
ID: Rincell-1
2026-05-31
Open source
Rincell-1 by Rinri Therapeutics
Rinri Therapeutics
TherapeuticCell Therapy
Company Sourcerinri-therapeutics.com
Clinical Trial
Priority: Top priority
Confidence: 92%
Phase 1/2Active
Development StageCurrent StatusNotes
ID: Rincell-1
2026-05-31
Open source
Rincell-1 by Rinri Therapeutics
Rinri Therapeutics
TherapeuticCell Therapy
Manual Curationhra.nhs.uk
Clinical Trial
Priority: Top priority
Confidence: 92%
Phase 1/2Active
Trial IDsPatient PopulationGeography
ID: R1-25
2026-05-31
Open source
Advanced Bionics HiRes Ultra 3D and Naída CI Marvel Platform
Advanced Bionics
DeviceCochlear/Auditory Implant
Company Sourceadvancedbionics.com
Company Source
Priority: Top priority
Confidence: 91%
MarketedMarketed
Program NameAlternative NamesCompany or SponsorMechanismIndications+1
No source ID listed
2026-05-31
Open source
Advanced Bionics HiRes Ultra 3D and Naída CI Marvel Platform
Advanced Bionics
DeviceCochlear/Auditory Implant
Company Sourceadvancedbionics.com
Company Source
Priority: Top priority
Confidence: 91%
MarketedMarketed
Alternative NamesCurrent StatusNotes
No source ID listed
2026-05-31
Open source
Advanced Bionics HiRes Ultra 3D and Naída CI Marvel Platform
Advanced Bionics
DeviceCochlear/Auditory Implant
Regulatory Sourceaccessdata.fda.gov
Company Source
Priority: Top priority
Confidence: 91%
MarketedMarketed
NotesCurrent StatusKey Events
ID: Z-2032-2020
2026-05-31
Open source
AC102 by AudioCure Pharma
AudioCure Pharma
TherapeuticSmall Molecule
Company Sourceaudiocure.com
Clinical Trial
Priority: Top priority
Confidence: 91%
Phase 2Active
Program NameAlternative NamesCompany or SponsorMechanismIndications+1
ID: AC102
2026-05-31
Open source
AC102 by AudioCure Pharma
AudioCure Pharma
TherapeuticSmall Molecule
Company Sourceaudiocure.com
Clinical Trial
Priority: Top priority
Confidence: 91%
Phase 2Active
Development StageCurrent StatusGeographyNotes
ID: AC102, AC102-201
2026-05-31
Open source
AC102 by AudioCure Pharma
AudioCure Pharma
TherapeuticSmall Molecule
Manual Curationcenterwatch.com
Clinical Trial
Priority: Top priority
Confidence: 91%
Phase 2Active
Trial IDsPatient Population
ID: NCT05776459
2026-05-31
Open source
AC102 by AudioCure Pharma
AudioCure Pharma
TherapeuticSmall Molecule
Publicationpmc.ncbi.nlm.nih.gov
Clinical Trial
Priority: Top priority
Confidence: 91%
Phase 2Active
MechanismNotes
ID: PMC11009624
2026-05-31
Open source
Natus ALGO 7i Newborn Hearing Screener
Natus
DiagnosticDiagnostic
Company Sourcenatus.com
Company Source
Priority: Priority 3
Confidence: 91%
MarketedMarketed
Program NameCompany or SponsorMechanismCurrent StatusRoute of Administration
No source ID listed
2026-05-31
Open source
Natus ALGO 7i Newborn Hearing Screener
Natus
DiagnosticDiagnostic
Regulatory Sourceaccessdata.fda.gov
Company Source
Priority: Priority 3
Confidence: 91%
MarketedMarketed
Alternative NamesNotesGeography
ID: K073665
2026-05-31
Open source
Signia Integrated Xperience
Signia
DeviceHearing Aid/Software
Company Sourcesignia.net
Company Source
Priority: Main database
Confidence: 91%
MarketedMarketed
Program NameAlternative NamesCompany or SponsorMechanismCurrent Status+1
No source ID listed
2026-05-31
Open source
Signia Integrated Xperience
Signia
DeviceHearing Aid/Software
Company Sourcewsa.com
Company Source
Priority: Main database
Confidence: 91%
MarketedMarketed
Key EventsNotesGeography
No source ID listed
2026-05-31
Open source
AK-antiVEGF by Eli Lilly and Akouos
Eli Lilly and Company
TherapeuticGene Therapy
Company Sourceakouos.com
Clinical Trial
Priority: Main database
Confidence: 90%
Phase 1/2Active
Program NameAlternative NamesCompany or SponsorRelated CompaniesTreatment or Product Type+6
ID: AK-antiVEGF, AAVAnc80-antiVEGF, NCT06517888
2026-06-09
Open source
AK-antiVEGF by Eli Lilly and Akouos
Eli Lilly and Company
TherapeuticGene Therapy
Clinical Trial Registryclinicaltrials.gov
Clinical Trial
Priority: Main database
Confidence: 90%
Phase 1/2Active
Trial IDsDevelopment StageCurrent StatusPatient PopulationGeography
ID: NCT06517888
2026-06-09
Open source
Clearly Audiobooks by BioSpeech
BioSpeech
Procedure/RehabBehavioral/Rehabilitation
Clinical Trial Registryclinicaltrials.gov
Trial Registry and Company Source
Priority: Main database
Confidence: 90%
Interventional/NACompleted
Program NameAlternative NamesCompany or SponsorRelated CompaniesProgram Category+11
ID: NCT04231396, Audiobooks for Hearing Loss App, BioSpeech, 1R44DC017403-01A1
2026-06-09
Open source
Clearly Audiobooks by BioSpeech
BioSpeech
Procedure/RehabBehavioral/Rehabilitation
Company Sourcebiospeech.com
Trial Registry and Company Source
Priority: Main database
Confidence: 90%
Interventional/NACompleted
Program NameAlternative NamesCompany or SponsorMechanismRoute of Administration+1
ID: Clearly Audiobooks, BioSpeech
2026-06-09
Open source
Clearly Audiobooks by BioSpeech
BioSpeech
Procedure/RehabBehavioral/Rehabilitation
Company Sourcebiospeech.com
Trial Registry and Company Source
Priority: Main database
Confidence: 90%
Interventional/NACompleted
Company or SponsorNotes
ID: BioSpeech
2026-06-09
Open source
Auricle Tinnitus Device
Auricle Inc.
DeviceNeuromodulation
Company Sourceauricleinc.com
Company Source
Priority: Top priority
Confidence: 90%
Phase 2Active
Company or SponsorRelated CompaniesCurrent StatusNotes
No source ID listed
2026-05-31
Open source
Auricle Tinnitus Device
Auricle Inc.
DeviceNeuromodulation
Company Sourceauricleinc.com
Company Source
Priority: Top priority
Confidence: 90%
Phase 2Active
Program NameAlternative NamesCompany or SponsorRelated CompaniesNotes
No source ID listed
2026-05-31
Open source
Auricle Tinnitus Device
Auricle Inc.
DeviceNeuromodulation
Company Sourceauricleinc.com
Company Source
Priority: Top priority
Confidence: 90%
Phase 2Active
Program CategoryTreatment or Product TypeMechanismIndicationsCurrent Status+2
No source ID listed
2026-05-31
Open source
Auricle Tinnitus Device
Auricle Inc.
DeviceNeuromodulation
Company Sourceauricleinc.com
Company Source
Priority: Top priority
Confidence: 90%
Phase 2Active
Related CompaniesNotes
No source ID listed
2026-05-31
Open source
Auricle Tinnitus Device
Auricle Inc.
DeviceNeuromodulation
Publicationdx.doi.org
Company Source
Priority: Top priority
Confidence: 90%
Phase 2Active
Development StageNotes
No source ID listed
2026-05-31
Open source
Auricle Tinnitus Device
Auricle Inc.
DeviceNeuromodulation
Publicationscience.org
Company Source
Priority: Top priority
Confidence: 90%
Phase 2Active
MechanismNotes
No source ID listed
2026-05-31
Open source
EHT102 by EuHearing
Shanghai EuHearing Therapeutics Co., Ltd
TherapeuticGene Therapy
Clinical Trial Registryclinicaltrials.gov
Clinical Trial
Priority: Main database
Confidence: 90%
Phase 1/2Active
Program NameAlternative NamesCompany or SponsorDevelopment StageCurrent Status+6
ID: NCT07288580, EHT102, OTOF
2026-06-08
Open source
Vestipitant tinnitus study by GSK
GlaxoSmithKline
TherapeuticSmall Molecule
Company Sourcegsk-studyregister.com
Company Source
Priority: Priority 3
Confidence: 90%
Phase 2Completed
Program NameAlternative NamesCompany or SponsorDevelopment StageCurrent Status+6
ID: NKP106254, NCT00394056, vestipitant, paroxetine
2026-06-09
Open source
Vestipitant tinnitus study by GSK
GlaxoSmithKline
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Company Source
Priority: Priority 3
Confidence: 90%
Phase 2Completed
Program NameAlternative NamesCompany or SponsorRelated CompaniesIndustry Sponsorship+8
ID: NCT00394056, NKP106254, GW597599
2026-06-09
Open source
Vestipitant tinnitus study by GSK
GlaxoSmithKline
TherapeuticSmall Molecule
Publicationpubmed.ncbi.nlm.nih.gov
Company Source
Priority: Priority 3
Confidence: 90%
Phase 2Completed
NotesCurrent StatusKey Events
ID: PMID 21646935, Roberts 2011, DOI 10.1097/MAO.0b013e318218a086
2026-06-09
Open source
Vestipitant tinnitus study by GSK
GlaxoSmithKline
TherapeuticSmall Molecule
Compound Databasepubchem.ncbi.nlm.nih.gov
Company Source
Priority: Priority 3
Confidence: 90%
Phase 2Completed
Alternative NamesTreatment or Product TypeMechanism
ID: PubChem CID 9832383, Vestipitant, S052TOI9BI
2026-06-09
Open source
hearX hearTest
hearX
DiagnosticDiagnostic
Company Sourcehearxgroup.com
Company Source
Priority: Priority 3
Confidence: 90%
MarketedMarketed
Program NameCompany or SponsorMechanismCurrent StatusRoute of Administration
No source ID listed
2026-05-31
Open source
hearX hearTest
hearX
DiagnosticDiagnostic
Company Sourcehearxgroup.com
Company Source
Priority: Priority 3
Confidence: 90%
MarketedMarketed
IndicationsNotesGeography
No source ID listed
2026-05-31
Open source
hearX hearTest
hearX
DiagnosticDiagnostic
Company Sourcehearxgroup.com
Company Source
Priority: Priority 3
Confidence: 90%
MarketedMarketed
Alternative NamesPatient PopulationRoute of Administration
No source ID listed
2026-05-31
Open source
OTO-104 (dexamethasone) by Otonomy
Otonomy
TherapeuticSteroid/Anti-inflammatory
Publicationpmc.ncbi.nlm.nih.gov
Publication
Priority: Priority 3
Confidence: 90%
Phase 3Discontinued
Program NameAlternative NamesCompany or SponsorTreatment or Product TypeMechanism+4
ID: OTO-104, NCT02612337, NCT02727442, NCT03664674
2026-06-09
Open source
OTO-104 (dexamethasone) by Otonomy
Otonomy
TherapeuticSteroid/Anti-inflammatory
Publicationpmc.ncbi.nlm.nih.gov
Publication
Priority: Priority 3
Confidence: 90%
Phase 3Discontinued
MechanismRoute of AdministrationPatient PopulationNotes
ID: OTO-104, NCT01412177
2026-06-09
Open source
OTO-104 (dexamethasone) by Otonomy
Otonomy
TherapeuticSteroid/Anti-inflammatory
Clinical Trial Registryclinicaltrials.gov
Publication
Priority: Priority 3
Confidence: 90%
Phase 3Discontinued
Trial IDsDevelopment StageCurrent StatusIndicationsGeography
ID: NCT01412177, OTO-104
2026-06-09
Open source
OTO-104 (dexamethasone) by Otonomy
Otonomy
TherapeuticSteroid/Anti-inflammatory
Clinical Trial Registryclinicaltrials.gov
Publication
Priority: Priority 3
Confidence: 90%
Phase 3Discontinued
Trial IDsIndicationsDevelopment StageCurrent StatusPatient Population
ID: NCT02997189, OTO-104
2026-06-09
Open source
OTO-104 (dexamethasone) by Otonomy
Otonomy
TherapeuticSteroid/Anti-inflammatory
Company Sourceglobenewswire.com
Publication
Priority: Priority 3
Confidence: 90%
Phase 3Discontinued
Company or SponsorDevelopment StageKey Events
ID: OTO-104
2026-06-09
Open source
OTO-104 (dexamethasone) by Otonomy
Otonomy
TherapeuticSteroid/Anti-inflammatory
Clinical Trial Registryclinicaltrials.gov
Publication
Priority: Priority 3
Confidence: 90%
Phase 3Discontinued
Alternative NamesTrial IDsDevelopment StageCurrent StatusRoute of Administration+3
ID: NCT01084525, OTO-104, OTO-104 (steroid) 3 mg, OTO-104 (steroid) 12 mg
2026-06-09
Open source
Phonak Lyric
Phonak
DeviceHearing Aid/Software
Company Sourcephonak.com
Company Source
Priority: Main database
Confidence: 90%
MarketedMarketed
Program NameCompany or SponsorMechanismCurrent StatusRoute of Administration
No source ID listed
2026-05-31
Open source
Phonak Lyric
Phonak
DeviceHearing Aid/Software
Company Sourcephonak.com
Company Source
Priority: Main database
Confidence: 90%
MarketedMarketed
NotesAlternative NamesCurrent Status
No source ID listed
2026-05-31
Open source
ReSound Vivia
GN ReSound
DeviceHearing Aid/Software
Company Sourcepro.resound.com
Company Source
Priority: Top priority
Confidence: 90%
MarketedMarketed
Program NameAlternative NamesCompany or SponsorMechanismCurrent Status
No source ID listed
2026-05-31
Open source
ReSound Vivia
GN ReSound
DeviceHearing Aid/Software
Company Sourceresound.com
Company Source
Priority: Top priority
Confidence: 90%
MarketedMarketed
IndicationsRoute of AdministrationGeography
No source ID listed
2026-05-31
Open source
SPI-1005 by Sound Pharmaceuticals
Sound Pharmaceuticals
TherapeuticSmall Molecule
Company Sourcesoundpharma.com
Clinical Trial
Priority: Top priority
Confidence: 90%
Phase 3Active
Program NameCompany or SponsorMechanismIndicationsNotes
ID: SPI-1005
2026-05-31
Open source
SPI-1005 by Sound Pharmaceuticals
Sound Pharmaceuticals
TherapeuticSmall Molecule
Company Sourcesoundpharma.com
Clinical Trial
Priority: Top priority
Confidence: 90%
Phase 3Active
Development StageCurrent StatusNotes
ID: SPI-1005, STOPMD-3
2026-05-31
Open source
SPI-1005 by Sound Pharmaceuticals
Sound Pharmaceuticals
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Clinical Trial
Priority: Top priority
Confidence: 90%
Phase 3Active
Trial IDsRoute of Administration
ID: NCT02603081
2026-05-31
Open source
SPI-1005 by Sound Pharmaceuticals
Sound Pharmaceuticals
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Clinical Trial
Priority: Top priority
Confidence: 90%
Phase 3Active
Trial IDsIndications
ID: NCT02779192
2026-05-31
Open source
SPI-1005 by Sound Pharmaceuticals
Sound Pharmaceuticals
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Clinical Trial
Priority: Top priority
Confidence: 90%
Phase 3Active
Trial IDsIndications
ID: NCT02819856
2026-05-31
Open source
SPI-1005 by Sound Pharmaceuticals
Sound Pharmaceuticals
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Clinical Trial
Priority: Top priority
Confidence: 90%
Phase 3Active
Trial IDsDevelopment StageIndications
ID: NCT03325790
2026-05-31
Open source
Starkey Edge AI
Starkey
DeviceHearing Aid/Software
Company Sourcestarkey.com
Company Source
Priority: Main database
Confidence: 90%
MarketedMarketed
Program NameCompany or SponsorMechanismCurrent StatusRoute of Administration
No source ID listed
2026-05-31
Open source
Starkey Edge AI
Starkey
DeviceHearing Aid/Software
Company Sourcestarkey.com
Company Source
Priority: Main database
Confidence: 90%
MarketedMarketed
Key EventsNotesGeography
No source ID listed
2026-05-31
Open source
Sun Yat-sen NAD+ Coenzyme I SSNHL Study
Institution-led study
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Trial Registry and Publication
Priority: Priority 3
Confidence: 90%
Phase 1Completed
Program NameAlternative NamesCompany or SponsorProgram CategoryTreatment or Product Type+6
ID: NCT05849519
2026-06-10
Open source
Sun Yat-sen NAD+ Coenzyme I SSNHL Study
Institution-led study
TherapeuticSmall Molecule
Publicationpubmed.ncbi.nlm.nih.gov
Trial Registry and Publication
Priority: Priority 3
Confidence: 90%
Phase 1Completed
Program NameAlternative NamesMechanismCurrent StatusPatient Population+2
ID: PMID:41035311, PMCID:PMC12913733, NCT05849519
2026-06-10
Open source
Sun Yat-sen NAD+ Coenzyme I SSNHL Study
Institution-led study
TherapeuticSmall Molecule
Publicationpmc.ncbi.nlm.nih.gov
Trial Registry and Publication
Priority: Priority 3
Confidence: 90%
Phase 1Completed
Program NameAlternative NamesMechanismCurrent StatusPatient Population+2
ID: PMCID:PMC12913733, NCT05849519
2026-06-10
Open source
Sun Yat-sen NAD+ Coenzyme I SSNHL Study
Institution-led study
TherapeuticSmall Molecule
Publicationonlinelibrary.wiley.com
Trial Registry and Publication
Priority: Priority 3
Confidence: 90%
Phase 1Completed
Program NameMechanismCurrent StatusNotesKey Events
ID: DOI:10.1002/lary.70173, NCT05849519
2026-06-10
Open source
Sun Yat-sen NAD+ Coenzyme I SSNHL Study
Institution-led study
TherapeuticSmall Molecule
Trial Registry Mirrorichgcp.net
Trial Registry and Publication
Priority: Priority 3
Confidence: 90%
Phase 1Completed
Program NameAlternative NamesDevelopment StageRoute of AdministrationNotes
ID: NCT05849519
2026-06-10
Open source
Widex Allure
Widex
DeviceHearing Aid/Software
Company Sourcewidex.com
Company Source
Priority: Main database
Confidence: 90%
MarketedMarketed
Program NameCompany or SponsorMechanismCurrent StatusRoute of Administration
No source ID listed
2026-05-31
Open source
Widex Allure
Widex
DeviceHearing Aid/Software
Company Sourcewsa.com
Company Source
Priority: Main database
Confidence: 90%
MarketedMarketed
Alternative NamesKey EventsNotesGeography
No source ID listed
2026-05-31
Open source
hearX hearScreen
hearX
DiagnosticDiagnostic
Company Sourcehearxgroup.com
Company Source
Priority: Priority 3
Confidence: 89%
MarketedMarketed
Program NameCompany or SponsorMechanismCurrent StatusRoute of Administration+1
No source ID listed
2026-05-31
Open source
hearX hearScreen
hearX
DiagnosticDiagnostic
Company Sourcehearxgroup.com
Company Source
Priority: Priority 3
Confidence: 89%
MarketedMarketed
IndicationsNotesGeography
No source ID listed
2026-05-31
Open source
NHPN-1010
Otologic Pharmaceutics
TherapeuticSmall Molecule
Company Sourcehoughear.org
Company Source
Priority: Main database
Confidence: 89%
Phase 1Completed
Program NameCompany or SponsorRelated CompaniesDevelopment StageCurrent Status+1
ID: NHPN-1010
2026-05-31
Open source
NHPN-1010
Otologic Pharmaceutics
TherapeuticSmall Molecule
Company Sourceotologicpharma.com
Company Source
Priority: Main database
Confidence: 89%
Phase 1Completed
MechanismIndicationsRoute of AdministrationNotes
ID: NHPN-1010
2026-05-31
Open source
NHPN-1010
Otologic Pharmaceutics
TherapeuticSmall Molecule
Company Sourcehoughear.org
Company Source
Priority: Main database
Confidence: 89%
Phase 1Completed
Alternative NamesDevelopment StageCurrent Status
ID: NHPN-1010
2026-05-31
Open source
NHPN-1010
Otologic Pharmaceutics
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Company Source
Priority: Main database
Confidence: 89%
Phase 1Completed
Trial IDsDevelopment StageCurrent StatusRoute of AdministrationPatient Population+1
ID: NCT02259595, HPN-07, NAC
2026-05-31
Open source
Bio-logic NavPRO ONE
Natus
DiagnosticDiagnostic
Company Sourcenatus.com
Company Source
Priority: Priority 3
Confidence: 89%
MarketedMarketed
Program NameAlternative NamesCompany or SponsorMechanismCurrent Status+1
No source ID listed
2026-05-31
Open source
Bio-logic NavPRO ONE
Natus
DiagnosticDiagnostic
Company Sourcenatus.com
Company Source
Priority: Priority 3
Confidence: 89%
MarketedMarketed
IndicationsGeographyNotes
No source ID listed
2026-05-31
Open source
CGF166 by Novartis
Novartis
TherapeuticGene Therapy
Company Sourcenovartis.com
Clinical Trial
Priority: Main database
Confidence: 89%
Phase 1/2Completed
Program NameCompany or SponsorMechanismTarget GeneIndications
ID: CGF166
2026-05-31
Open source
CGF166 by Novartis
Novartis
TherapeuticGene Therapy
Clinical Trial Registryclinicaltrials.gov
Clinical Trial
Priority: Main database
Confidence: 89%
Phase 1/2Completed
Trial IDsDevelopment StageRoute of AdministrationPatient PopulationGeography
ID: NCT02132130
2026-05-31
Open source
CGF166 by Novartis
Novartis
TherapeuticGene Therapy
Company Sourcenovctrd.com
Clinical Trial
Priority: Main database
Confidence: 89%
Phase 1/2Completed
Route of AdministrationTarget GeneNotes
ID: CGF166
2026-05-31
Open source
Oticon Intent
Oticon
DeviceHearing Aid/Software
Company Sourceoticon.com
Company Source
Priority: Main database
Confidence: 89%
MarketedMarketed
Program NameCompany or SponsorCurrent StatusRoute of AdministrationGeography
No source ID listed
2026-05-31
Open source
Oticon Intent
Oticon
DeviceHearing Aid/Software
Company Sourceoticon.com
Company Source
Priority: Main database
Confidence: 89%
MarketedMarketed
Alternative NamesMechanismIndicationsPatient Population
No source ID listed
2026-05-31
Open source
AP-HP OTOPLAT platinum ototoxicity pharmacogenetics study
Institution-led study
DiagnosticGenetic/Biomarker Study
Clinical Trial Registryclinicaltrials.gov
Trial Registry
Priority: Priority 3
Confidence: 88%
Not applicableCompleted
Program NameCompany or SponsorRelated CompaniesIndustry SponsorshipProgram Category+11
ID: NCT02425397
2026-06-10
Open source
LY3056480 by Audion Therapeutics
Audion Therapeutics BV
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Publication
Priority: Priority 3
Confidence: 88%
Phase 2Discontinued
Program NameAlternative NamesCompany or SponsorRelated CompaniesIndustry Sponsorship+12
ID: NCT05061758, AUT-003, VESTA, LY3056480
2026-06-09
Open source
LY3056480 by Audion Therapeutics
Audion Therapeutics BV
TherapeuticSmall Molecule
Publicationnature.com
Publication
Priority: Priority 3
Confidence: 88%
Phase 2Discontinued
Program NameAlternative NamesCompany or SponsorRelated CompaniesTreatment or Product Type+8
ID: LY3056480, ISRCTN59733689, REGAIN, DOI 10.1038/s41467-024-45784-0, PMID 38429256
2026-06-09
Open source
LY3056480 by Audion Therapeutics
Audion Therapeutics BV
TherapeuticSmall Molecule
Publicationpubmed.ncbi.nlm.nih.gov
Publication
Priority: Priority 3
Confidence: 88%
Phase 2Discontinued
Trial IDsDevelopment StageCurrent StatusNotesKey Events
ID: PMID 38429256, LY3056480, ISRCTN59733689
2026-06-09
Open source
LY3056480 by Audion Therapeutics
Audion Therapeutics BV
TherapeuticSmall Molecule
Institution Sourceucl.ac.uk
Publication
Priority: Priority 3
Confidence: 88%
Phase 2Discontinued
Current StatusNotesKey Events
ID: LY3056480, REGAIN, Audion Therapeutics
2026-06-09
Open source
MED-EL BONEBRIDGE BCI 602 pediatric premarket study
MED-EL
DeviceCochlear/Auditory Implant
Clinical Trial Registryclinicaltrials.gov
Trial Registry and Company Source
Priority: Priority 3
Confidence: 88%
Observational/NACompleted
Program NameCompany or SponsorDevelopment StageCurrent StatusIndications+4
ID: NCT06634784, 2023BB006, CIV-24-01-045738
2026-06-09
Open source
MED-EL BONEBRIDGE BCI 602 pediatric premarket study
MED-EL
DeviceCochlear/Auditory Implant
Company Sourcemedel.com
Trial Registry and Company Source
Priority: Priority 3
Confidence: 88%
Observational/NACompleted
Alternative NamesTreatment or Product TypeMechanismIndicationsRoute of Administration
ID: BONEBRIDGE
2026-06-09
Open source
SoundMind customized sound therapy tinnitus study
Institution-led study
Procedure/RehabDigital Sound Therapy/Rehabilitation
Clinical Trial Registryclinicaltrials.gov
Trial Registry
Priority: Priority 3
Confidence: 88%
Not applicableCompleted
Program NameCompany or SponsorRelated CompaniesIndustry SponsorshipProgram Category+11
ID: NCT05963542
2026-06-10
Open source
Audiovestibular biomarker DNA biobanking study
Institution-led study
DiagnosticGenetic/Biomarker Study
Clinical Trial Registryclinicaltrials.gov
Trial Registry
Priority: Priority 3
Confidence: 88%
Not applicableCompleted
Program NameCompany or SponsorRelated CompaniesIndustry SponsorshipProgram Category+11
ID: NCT04200664
2026-06-10
Open source
Antidepressant plus hearing-aid mood and cognition study
Institution-led study
Procedure/RehabHearing Aid/Medication Combination Study
Clinical Trial Registryclinicaltrials.gov
Trial Registry
Priority: Priority 3
Confidence: 88%
Phase 4Completed
Program NameCompany or SponsorRelated CompaniesIndustry SponsorshipProgram Category+11
ID: NCT03321006
2026-06-10
Open source
Eargo self-fitting hearing aid validation study
Institution-led study
Software/NeurotechHearing Aid/Software
Clinical Trial Registryclinicaltrials.gov
Trial Registry
Priority: Priority 3
Confidence: 88%
Not applicableCompleted
Program NameCompany or SponsorRelated CompaniesIndustry SponsorshipProgram Category+11
ID: NCT05246904
2026-06-10
Open source
Nantong newborn deafness-gene screening cohort
Institution-led study
DiagnosticGenetic Screening Test
Clinical Trial Registryclinicaltrials.gov
Trial Registry
Priority: Priority 3
Confidence: 88%
Not applicableActive
Program NameCompany or SponsorRelated CompaniesIndustry SponsorshipProgram Category+11
ID: NCT06133946
2026-06-10
Open source
Real-ear measurement hearing-aid fitting study
Institution-led study
Software/NeurotechHearing Aid/Software
Clinical Trial Registryclinicaltrials.gov
Trial Registry
Priority: Priority 3
Confidence: 88%
Not applicableCompleted
Program NameCompany or SponsorRelated CompaniesIndustry SponsorshipProgram Category+11
ID: NCT05621798
2026-06-10
Open source
Hebei gastrodin acupoint injection SNHL vertigo study
Institution-led study
TherapeuticSmall Molecule/Acupoint Injection
Clinical Trial Registryclinicaltrials.gov
Trial Registry
Priority: Priority 3
Confidence: 88%
Not applicableCompleted
Program NameCompany or SponsorRelated CompaniesIndustry SponsorshipProgram Category+11
ID: NCT07283562
2026-06-10
Open source
HG205 RNA base-editing therapy by HuidaGene
HuidaGene Therapeutics Co., Ltd.
TherapeuticRNA Therapy
Clinical Trial Registryclinicaltrials.gov
Trial Registry
Priority: Priority 3
Confidence: 88%
Early Phase 1Discontinued
Program NameAlternative NamesCompany or SponsorRelated CompaniesTreatment or Product Type+8
ID: NCT06025032, HG20501, HG205
2026-06-09
Open source
Isosorbide Oral Solution by Lunan Better Pharmaceutical
Lunan Better Pharmaceutical Co., Ltd.
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Clinical Trial
Priority: Main database
Confidence: 88%
Phase 2/3Active
Program NameCompany or SponsorDevelopment StageCurrent StatusRoute of Administration+4
ID: NCT06765993, BT-YSLC-001, Isosorbide oral solution
2026-06-08
Open source
MEEI sudden deafness steroid treatment trial
Institution-led study
TherapeuticSteroid/Anti-inflammatory
Clinical Trial Registryclinicaltrials.gov
Trial Registry Results and Publication
Priority: Priority 3
Confidence: 88%
Phase 3Completed
Program NameAlternative NamesRelated CompaniesIndustry SponsorshipDevelopment Stage+6
ID: NCT00097448
2026-06-09
Open source
MEEI sudden deafness steroid treatment trial
Institution-led study
TherapeuticSteroid/Anti-inflammatory
Publicationpubmed.ncbi.nlm.nih.gov
Trial Registry Results and Publication
Priority: Priority 3
Confidence: 88%
Phase 3Completed
Current StatusMechanismNotesKey Events
ID: PMID:21610239
2026-06-09
Open source
MEEI sudden deafness steroid treatment trial
Institution-led study
TherapeuticSteroid/Anti-inflammatory
Publicationpubmed.ncbi.nlm.nih.gov
Trial Registry Results and Publication
Priority: Priority 3
Confidence: 88%
Phase 3Completed
NotesKey Events
ID: PMID:22805100
2026-06-09
Open source
Nottingham Auditory Games for Tinnitus Training Study
Institution-led study
Software/NeurotechBehavioral/Rehabilitation
Clinical Trial Registryclinicaltrials.gov
Trial Registry and Publication
Priority: Priority 3
Confidence: 88%
Phase 1Completed
Program NameAlternative NamesCompany or SponsorRelated CompaniesProgram Category+8
ID: NCT02095262, 11IH001
2026-06-10
Open source
Nottingham Auditory Games for Tinnitus Training Study
Institution-led study
Software/NeurotechBehavioral/Rehabilitation
Publicationpmc.ncbi.nlm.nih.gov
Trial Registry and Publication
Priority: Priority 3
Confidence: 88%
Phase 1Completed
Program NameAlternative NamesRelated CompaniesMechanismCurrent Status+2
ID: NCT02095262
2026-06-10
Open source
Nottingham Auditory Games for Tinnitus Training Study
Institution-led study
Software/NeurotechBehavioral/Rehabilitation
Trial Registry Mirrorichgcp.net
Trial Registry and Publication
Priority: Priority 3
Confidence: 88%
Phase 1Completed
Program NameAlternative NamesCompany or SponsorDevelopment StageCurrent Status+1
ID: NCT02095262
2026-06-10
Open source
Nottingham Auditory Games for Tinnitus Training Study
Institution-led study
Software/NeurotechBehavioral/Rehabilitation
Trial Registry Mirrorctv.veeva.com
Trial Registry and Publication
Priority: Priority 3
Confidence: 88%
Phase 1Completed
Program NameAlternative NamesDevelopment StageCurrent StatusNotes
ID: NCT02095262
2026-06-10
Open source
National Taiwan University NAC Noise-Induced Hearing Loss Study
Institution-led study
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Trial Registry and Publication
Priority: Priority 3
Confidence: 88%
Phase 2Completed
Program NameAlternative NamesCompany or SponsorRelated CompaniesIndustry Sponsorship+11
ID: NCT00552786
2026-06-10
Open source
National Taiwan University NAC Noise-Induced Hearing Loss Study
Institution-led study
TherapeuticSmall Molecule
Trial Registry Mirrorichgcp.net
Trial Registry and Publication
Priority: Priority 3
Confidence: 88%
Phase 2Completed
Program NameAlternative NamesCompany or SponsorRelated CompaniesDevelopment Stage+3
ID: NCT00552786
2026-06-10
Open source
National Taiwan University NAC Noise-Induced Hearing Loss Study
Institution-led study
TherapeuticSmall Molecule
Publicationresearchoutput.ncku.edu.tw
Trial Registry and Publication
Priority: Priority 3
Confidence: 88%
Phase 2Completed
Program NameMechanismIndicationsNotesKey Events
ID: NCT00552786
2026-06-10
Open source
National Taiwan University NAC Noise-Induced Hearing Loss Study
Institution-led study
TherapeuticSmall Molecule
Publicationpmc.ncbi.nlm.nih.gov
Trial Registry and Publication
Priority: Priority 3
Confidence: 88%
Phase 2Completed
Development StageCurrent StatusRoute of AdministrationPatient PopulationNotes
ID: NCT00552786
2026-06-10
Open source
Pamukkale local dexamethasone cochlear implant study
Institution-led study
TherapeuticSteroid/Anti-inflammatory
Clinical Trial Registryclinicaltrials.gov
Trial Registry
Priority: Priority 3
Confidence: 88%
Not applicableCompleted
Program NameCompany or SponsorRelated CompaniesIndustry SponsorshipProgram Category+11
ID: NCT04397354
2026-06-10
Open source
PF-04958242 by Biogen/Pfizer for age-related hearing loss
Biogen
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Publication
Priority: Priority 3
Confidence: 88%
Phase 1Completed
Program NameCompany or SponsorRelated CompaniesIndicationsDevelopment Stage+6
ID: NCT01518920, B1701005, PF-04958242
2026-06-09
Open source
PF-04958242 by Biogen/Pfizer for age-related hearing loss
Biogen
TherapeuticSmall Molecule
Publicationpubmed.ncbi.nlm.nih.gov
Publication
Priority: Priority 3
Confidence: 88%
Phase 1Completed
MechanismProgram CategoryTreatment or Product TypeCurrent StatusNotes+1
ID: 25997115, PF-04958242, 10.1001/jamaoto.2015.0791
2026-06-09
Open source
Regensburg rTMS tinnitus duration and frequency study
Institution-led study
Procedure/RehabNeuromodulation
Clinical Trial Registryclinicaltrials.gov
Trial Registry
Priority: Priority 3
Confidence: 88%
Not applicableCompleted
Program NameCompany or SponsorRelated CompaniesIndustry SponsorshipProgram Category+11
ID: NCT02653547
2026-06-10
Open source
São Paulo topical lidocaine tinnitus study
Institution-led study
TherapeuticSmall Molecule
Clinical Trial Registryclinicaltrials.gov
Trial Registry
Priority: Priority 3
Confidence: 88%
Not applicableCompleted
Program NameCompany or SponsorRelated CompaniesIndustry SponsorshipProgram Category+11
ID: NCT05711641
2026-06-10
Open source
GJB2-GT by Sensorion
Sensorion
TherapeuticGene Therapy
Company Sourcesensorion.com
Company Source
Priority: Main database
Confidence: 88%
PreclinicalActive
Program NameAlternative NamesCompany or SponsorRelated CompaniesTarget Gene+2
ID: GJB2-GT
2026-05-31
Open source
GJB2-GT by Sensorion
Sensorion
TherapeuticGene Therapy
Company Sourcebiospace.com
Company Source
Priority: Main database
Confidence: 88%
PreclinicalActive
Alternative NamesDevelopment StageCurrent StatusNotes
ID: SENS-601, GJB2-GT
2026-05-31
Open source
SHOEBOX PureTest
SHOEBOX
DiagnosticDiagnostic
Company Sourceshoebox.md
Company Source
Priority: Priority 3
Confidence: 88%
MarketedMarketed
Program NameCompany or SponsorMechanismCurrent StatusRoute of Administration
No source ID listed
2026-05-31
Open source
SHOEBOX PureTest
SHOEBOX
DiagnosticDiagnostic
Company Sourceshoebox.md
Company Source
Priority: Priority 3
Confidence: 88%
MarketedMarketed
NotesGeographyCurrent Status
No source ID listed
2026-05-31
Open source